REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

Assessment of residual cholesterol and inflammatory risk factors: The prespecifed risk factors include CRP, SAA, TNF-α, IL-6, MCP-1, Lp-PLA2, PCSK-9, Lp(a)

Study summary

Intensive lipid-lowering therapy is a cornerstone treatment for coronary heart disease (CHD). However, coronary plaque progression persists in a subset of patients even under intensive lipid-lowering therapy, which may be associated with residual lipid and inflammatory risks. Current research in this area remains largely confined to post hoc analyses of randomized controlled trials , with a notable scarcity of prospective follow-up cohorts. The investigators propose that establishing a prospective cohort will provide more authentic insights into the associations between residual risk factors and plaque progression. In this project, the investigators aim to establish a well-characterized CHD cohort with comprehensive data collection, good compliance, and an appropriate sample size. By focusing on non-target lesions within the target vessel and utilizing intravascular ultrasound (IVUS), the investigators will investigate the impact of residual lipid and inflammatory risks on plaque progression during intensive lipid-lowering therapy.

Eligibility

Primary outcome measure(s)

• coronary plaque progression — 9 to 12 months after PCI
  percent change in plaque volume measured by IVUS

Trial sites (1)

More Shanghai Zhongshan Hospital trials in China

Other trials for the same condition